3-phenyl-1,4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
AssigneeHoechst Marion Roussel, Inc.
InventorsChristopher Robin Dalton, John Michael Kane, John Herr Kehne
Life of this patent
Estimating the term…
Abstract
This invention relates to the treatment of depression by administration of novel 3-(R.sub.n -phenyl)-1,4-dialkyl-1,2,4-triazolium salts of the formula ##STR1## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy, n is zero, 1 or 2, and R.sub.1 and R.sub.4 independently represent C.sub.1-3 lower alkyl; and A.sup.- represents a pharmaceutically acceptable anion.
Claims45
A compound of the formula ##STR7## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy;
- n is zero, 1 or 2;
- R.sub.1 and R.sub.4 independently represent C.sub.1-3 lower alkyl;
- and A.sup.- represents a pharmaceutically acceptable anion.
A method for the treatment of depression which comprises administering to a patient in need thereof an effective dose of a compound of the formula ##STR8## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy;
- n is zero, 1 or 2;
- R.sub.1 and R.sub.4 independently represent C.sub.1-3 lower alkyl;
- and A.sup.- represents a pharmaceutically acceptable anion.
A pharmaceutical composition which comprises a compound of the formula ##STR9## wherein R is halogen, trifluoromethyl, C.sub.1-4 lower alkyl or C.sub.1-4 lower alkoxy;
- n is zero, 1 or 2;
- R.sub.1 and R.sub.4 independently represent C.sub.1-3 lower alkyl;
- and A.sup.- represents a pharmaceutically acceptable anion;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.